EGFR and non-small cell lung carcinoma: In a previous phase I study, objective response was observed in four non-small-cell lung cancer patients with epidermal growth factor receptor mutation, and the DoR range was 5.6 to 15.7 + months when oleclumab was administered in combination with durvalumab [13].